GLIOBREAK Developing a new treatment and companion diagnostic to improve outcomes for glioblastoma patients
- Coordinator
- Beactica Therapeutics AB, Sweden
- Runs
- 1 May 2026 to 31 October 2028
- Status
- Running
- EU funding
- €2.6m
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- European Innovation Council
- Grant agreement
- 101292011
What the project is doing
In the project's own words, from its summary on CORDIS.
Glioblastoma (GBM) remains a devastating brain cancer with limited treatment advances and poor survival outcomes. The GLIOBREAK project aims to develop BEA-17, a first-in-class oral small molecule that degrades epigenetic regulators LSD1 and CoREST, thereby reversing GBM immune evasion and enhancing responsiveness to immunotherapy. The main objectives are to advance BEA-17 and its biomarker-driven companion diagnostic from validated laboratory stage (TRL4) to early clinical readiness (TRL6).
This will be achieved through scalable GMP manufacturing, GLP-compliant safety and pharmacokinetic studies, efficacy validation in preclinical models, biomarker discovery and validation, and regulatory preparation including orphan drug designation. GLIOBREAK directly addresses key challenges outlined in the EICT work programme by proposing a novel immuno-epigenetic therapy targeting GBM’s immunosuppressive microenvironment, combined with precision biomarker-based patient stratification to improve clinical outcomes.
This aligns with Europe’s Beating Cancer Plan and EU priorities for innovative, personalized oncology medicines. By integrating fundamental biological insights with cutting-edge therapeutic and diagnostic development, GLIOBREAK aims to deliver a transformative new treatment option for GBM patients and establish a platform for expanding into other difficult-to-treat cancers, reinforcing Europe’s leadership in precision immuno-oncology.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Beactica Therapeutics AB | Uppsala | Sweden | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI